Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant polio virus vaccine - Istari Oncology

Drug Profile

Recombinant polio virus vaccine - Istari Oncology

Alternative Names: Polio Virus Sabin-Rhinovirus Poliovirus; PVS-RIPO; Re-engineered poliovirus; Sabin type 1 polio vaccine - Istari Oncology

Latest Information Update: 05 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Duke University Medical Center
  • Developer Duke University Medical Center; Istari Oncology; National Cancer Institute (USA)
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I Malignant melanoma
  • Preclinical Breast cancer; Prostate cancer

Most Recent Events

  • 14 Oct 2019 Duke University plans a phase Ib trial for Malignant melanoma (Combination therapy, Late-stage disease, Recurrent, Second-line therapy or greater) in USA (Intralesional, Injection) (NCT04125719)
  • 04 Jun 2019 Istari Oncology in collaboration with Genentech and Duke University plans a phase Ib/II trial for Glioma (Combination therapy, Late-stage disease, Recurrent) in August 2019 in USA (Intratumoural) (NCT03973879)
  • 26 Nov 2018 Phase-I clinical trials in Malignant melanoma (Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (Intratumoural) (NCT03712358)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top